Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06154252 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

StatusRecruiting
PhasePhase 2/3
Started2023-12-20
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 69 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

2026-09-01
minor
Study Status, Contacts/Locations v68
Study sitescontacts updated at 1 of 35 sites
2026-08-20
minor
Study Status, Contacts/Locations v67
Study sitescontacts updated at 1 of 35 sites
2026-07-22
minor
Study Status, Contacts/Locations v66
Study sitescontacts updated at 1 of 35 sites
2026-07-20
minor
Study Status, Contacts/Locations v65
Study sitescontacts updated at 1 of 35 sites
2026-07-16
minor
Study Status, Contacts/Locations v64
Study sitescontacts updated at 3 of 35 sites
Show 45 earlier versions
2026-07-13
minor
Study Status, Contacts/Locations v63
Study sitesdetails revised at 1 of 35 sites
2026-07-07
minor
Study Status, Contacts/Locations v62
Study sitesdetails revised at 1 of 35 sites
2026-06-08
minor
Study Status v61
Re-verified, no change to tracked fields
2026-06-02
minor
Study Status, Contacts/Locations v60
Study sitesdetails revised at 5 of 35 sites
2026-05-12
minor
Study Status, Contacts/Locations v59
Study sitesdetails revised at 5 of 35 sites
2026-04-27
minor
Study Status, Contacts/Locations v58
Study sites34→35
2026-04-22
minor
Study Status, Contacts/Locations v57
Study sites33→34
2026-04-14
minor
Study Status, Contacts/Locations v56
Study sitesdetails revised at 1 of 33 sites
2026-04-09
minor
Study Status, Contacts/Locations v55
Study sites32→33
2026-04-07
minor
Study Status, Contacts/Locations v54
Study sitescontacts updated at 1 of 32 sites
2026-04-01
minor
Study Status, Contacts/Locations v53
Study sites31→32
2026-03-25
minor
Study Status, Contacts/Locations v52
Study sitesdetails revised at 1 of 31 sites
2026-03-17
minor
Study Status, Contacts/Locations v51
Study sitesdetails revised at 1 of 31 sites
2026-03-03
minor
Study Status, Contacts/Locations v50
Study sitesdetails revised at 1 of 31 sites
2026-02-23
minor
Study Status, Contacts/Locations v49
Study sites31 entries, revised
Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
2026-02-12
minor
Study Status, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v48
PhasePhase 1/2→Phase 2/3
Enrollment target24→74
Study sites25→31
Study arms1→3
Eligibility criteria+3 characters
[...] Rheumatology classification criteria Diagnosis of DM, ASyS, or IMNM Evidence of active disease, despite prior or current tr [...]
Secondary endpoints6 to 12 entries
ToIncidence evaluateof adverse events and laboratory abnormalities To characterize the pharmacodynamicsPharmacodynamics (PD) To characterize the pharmacokineticsPharmacokinetics (PK) ToChange evaluatein disease-related biomarkers of muscle inflammation ToChange evaluatein autoantibody-related biomarkers ToProportion evaluateof efficacyDM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids Propo [...]
Primary endpoints1 to 3 entries
ToPhase evaluate1/2: Incidence and severity of adverse events reported(AEs) Phase by2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
2025-10-21
minor
Study Status, Contacts/Locations v47
Study sites25 entries, revised
Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients University of Michigan - Accepting Young Adult and Juvenile Patients
2025-10-14
minor
Study Status, Outcome Measures, Eligibility v46
Eligibility criteria-83 characters
[...] sm/American College of Rheumatology classification criteria Presence of serum myositis-specific antibodies or myositis-associated autoantibody Evidence of active disease, despite prior or current treatme [...]
Secondary endpointsdetails revised at 2 of 6 entries
2025-10-06
minor
Study Status, Contacts/Locations v45
Study sites25 entries, revised
Hospital for Special Surgery - Accepting Adult and Juvenile Patients Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
2025-09-25
minor
Study Status, Contacts/Locations v44
Study sites21→25
2025-09-19
minor
Study Status, Contacts/Locations v43
Study sites20→21
2025-09-09
minor
Study Status, Arms and Interventions, Eligibility, Contacts/Locations v42
Study sites17→20
Eligibility criteria+95 characters
[...] matology classification criteria Diagnosis of DM, ASyS, IMNM based on the presence of serum myositis-specific antibodies Evidence of active disease, despite prior or current treatm [...] ging (MRI), or electromyography Presence of muscle weakness Other protocol-defined criteria apply. Exclusion Criteria: Contraindication to leukapheresis ⇅ moved History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites ⇅ moved Active infection requiring medical intervention at screening ⇅ moved Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastr [...] [...]
2025-07-15
minor
Study Status, Contacts/Locations v41
Study sitescontacts updated at 1 of 17 sites
2025-07-14
minor
Study Status, Contacts/Locations v40
Study sitesdetails revised at 1 of 17 sites
2025-06-04
minor
Study Status, Contacts/Locations v39
Study sitesdetails revised at 1 of 17 sites
2025-06-03
minor
Study Status, Contacts/Locations v38
Study sitescontacts updated at 1 of 17 sites
2025-05-20
minor
Study Status, Contacts/Locations v37
Study sitesdetails revised at 2 of 17 sites
2025-05-15
minor
Study Status, Contacts/Locations v36
Study sites16→17
2025-05-14
minor
Study Status, Contacts/Locations v35
Study sites15→16
2025-05-12
minor
Study Status, Contacts/Locations v34
Study sites14→15
2025-04-30
minor
Study Status, Contacts/Locations v33
Study sitesdetails revised at 1 of 14 sites
2025-04-22
minor
Study Status, Contacts/Locations v32
Study sitescontacts updated at 1 of 14 sites
2025-04-14
minor
Study Status, Contacts/Locations v31
Study sites12→14
2025-04-10
minor
Study Status, Contacts/Locations v30
Study sites11→12
2025-02-26
minor
Study Status, Contacts/Locations v29
Study sitescontacts updated at 1 of 11 sites
2025-02-18
minor
Study Identification, Study Status, Oversight, Contacts/Locations v28
Study sitesdetails revised at 6 of 11 sites
Study titlerevised
RESET-Myositis: anAn Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects withWith Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
2025-02-06
minor
Study Identification, Study Status, Oversight, Contacts/Locations v27
Study sitesdetails revised at 7 of 11 sites
Study titlerevised
RESET-Myositis: Anan Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects Withwith Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
2024-12-20
minor
Study Identification, Study Status, Study Description, Conditions, Study Design, Arms and Interventions, Eligibility, Contacts/Locations v26
Enrollment target18→24
Eligibility criteria+1,479 characters
Adult Cohorts Inclusion Criteria: Age ≥18 and ≤75 A clinical diagnosis of [...] cant lung or cardiac impairment Previous CAR T cell therapy Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant Juvenile Cohort Inclusion Criteria: Age ≥6 and ≤17 years at enrollment A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification crit [...] Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Study description+55 characters
[...] ding dermatomyositis (DM), anti-synthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to att [...] apy, CABA-201, that can be given to patients with DM, ASyS, andIMNM, IMNMor JIIM who have active disease. A single dose of CABA-201 in combi [...]
Study sites11 entries, revised
University of California Irvine - Accepting Adult Patients Mayo Clinic Florida - Accepting Adult Patients Northwestern Memorial Hospital - Accepting Adult Patients The University of Chicago Medical Center - Accepting Adult and Juvenile Patients University of Kansas Medical Center - Accepting Adult Patients Mayo Clinic - Accepting Adult Patients Oregon Health & Science University - Accepting Adult Patients Vanderbilt University Medical Center - Accepting Adult Patients Houston Methodist Hospital - Accepting Adult Patients University of Texas MD Anderson Cancer Center - Accepting Adult Patients [...] [...]
Study title+45 characters
[...] 201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
2024-12-13
minor
2 amendments v24-v25
2 re-verifications since 2024-12-11, no change to tracked fields
2024-12-09
minor
Study Status, Contacts/Locations v23
Study sites10→11
2024-11-27
minor
Study Identification, Study Status, Oversight, Contacts/Locations v22
Study sitesdetails revised at 6 of 10 sites
Study titlerevised
RESET-Myositis: anAn Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects withWith Active Idiopathic Inflammatory Myopathy
2024-09-13
minor
Study Status, Contacts/Locations v21
Study sites8→10
2024-09-06
minor
Study Identification, Study Status, Oversight, Contacts/Locations v20
Study sitesdetails revised at 4 of 8 sites
Study titlerevised
RESET-Myositis: Anan Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects Withwith Active Idiopathic Inflammatory Myopathy
2024-08-13
minor
Study Status, Contacts/Locations v19
Study sitescontacts updated at 1 of 8 sites
6 trials monitored
See 1 trial at risk
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Trial Details
NCT Number NCT06154252
Lead Sponsor Cabaletta Bio
Conditions Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Enrollment 74 participants
Start Date 2023-12-20
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-09-17